The clinical efficacy and safety of sulbactam plus cefoperazone (SBT/CPZ) was evaluated. Twenty-three selected patients with debilitating serious infections following major surgical interventions were treated with SBT/CPZ in a ratio of 1:1 (weight/weight) by intravenous infusion for seven to 15 days (average, 8.9 days). Twenty patients (87%) were infected with beta-lactamase-producing bacteria, 48% of which were resistant to multiple cephalosporins. The overall clinical efficacy rate reached 91%. Both clinical cure and bacteriological eradication were achieved in 7% of the patients, while partial eradication occurred in 17%. Significant adverse effects were noted in two patients (9%). Together with supportive measures, SBT/CPZ proved to be an effective and safe antibiotic for critically ill surgical patients.